These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23962533)

  • 1. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
    Wassil J; Huels J; Narasimhan V
    Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533
    [No Abstract]   [Full Text] [Related]  

  • 2. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal disease: Can we predict the unpredictable?
    Martinón-Torres F; Trilla A
    Med Clin (Barc); 2020 Jan; 154(1):20-22. PubMed ID: 31350058
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.
    Granoff DM
    Pediatr Infect Dis J; 2013 Apr; 32(4):372-3. PubMed ID: 23263177
    [No Abstract]   [Full Text] [Related]  

  • 10. Pros and cons of vaccination against serogroup B meningococcal disease.
    Delgado Rodríguez M; Domínguez García Á
    Med Clin (Barc); 2018 Feb; 150(3):109-113. PubMed ID: 28992986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
    Rappuoli R; Pizza M; Black S; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893
    [No Abstract]   [Full Text] [Related]  

  • 12. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The yin and yang of fever after meningococcal B vaccination.
    Ladhani SN; Riordan A
    Arch Dis Child; 2017 Oct; 102(10):881-882. PubMed ID: 28931534
    [No Abstract]   [Full Text] [Related]  

  • 15. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 17. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
    Andrews SM; Pollard AJ
    Lancet Infect Dis; 2014 May; 14(5):426-34. PubMed ID: 24679664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of serogroup B meningococcal disease.
    Stephens DS
    Lancet; 2012 Feb; 379(9816):592-4. PubMed ID: 22260987
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging experience with meningococcal serogroup B protein vaccines.
    Toneatto D; Pizza M; Masignani V; Rappuoli R
    Expert Rev Vaccines; 2017 May; 16(5):433-451. PubMed ID: 28375029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MenB candidate vaccine Bexsero induces robust immune response in infants.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Mar; 8(3):282. PubMed ID: 23213659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.